Self-Injected Antiplatelet for Acute MI Enters Phase 3 Testing
Medscape,
A phase 3 study testing the safety and efficacy of the fast-acting, self-administered P2Y12 receptor antagonist selatogrel (Idors…
A phase 3 study testing the safety and efficacy of the fast-acting, self-administered P2Y12 receptor antagonist selatogrel (Idors…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Idorsia Ltd (SIX: IDIA) today announced…
June 28, 2021 Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today…